The American Diabetes Associationrecommends GLP-1 RAs with proven cardiovascular benefit such as liraglutide,semaglutide or dulaglutide for patients with type 2 diabetes and establishedatherosclerotic cardiovascular disease or high cardiovascular risk irrespectiveof HbA1c level or background therapy. Here, GLP1R is linked to diabetes mellitus.